The effect of pharmacological PI3Kγ inhibitor on eotaxin-induced human eosinophil functions

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 2, 2014, Pages 164-169

  Saito, Yukiko ^a   Takeda, Masahide ^a   Nishikawa, Junko ^a   Konno, Yasunori ^a   Tamaki, Mami ^a   Itoga, Masamichi ^a   Kobayashi, Yoshiki ^a   Moritoki, Yuki ^a   Ito, Wataru ^a   Chihara, Junichi ^a   Ueki, Shigeharu ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Asthma; Eosinophil; Eotaxin

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; CHEMOKINE RECEPTOR CCR3; EOSINOPHIL PROTEIN X; EOTAXIN; G PROTEIN COUPLED RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-QUINOXALIN-6-YLMETHYLENETHIAZOLIDINE-2,4-DIONE; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CG PROTEIN, HUMAN; QUINOXALINE DERIVATIVE;

APOPTOSIS; ARTICLE; BOYDEN CHAMBER SYSTEM; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL SURVIVAL; CHEMOTAXIS; DEGRANULATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EOSINOPHIL; FLOW CYTOMETRY; GRANULOCYTE FUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION;

CHEMOKINE CCL11; CHEMOTAXIS; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; FLOW CYTOMETRY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; QUINOXALINES; THIAZOLIDINEDIONES;

EID: 84895922156     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.11.006     Document Type: Article

References (35)

1. Holgate S.T. Airway inflammation and remodeling in asthma: current concepts. Mol Biotechnol 2002, 22:179-189.
2. Rosenberg H.F., Phipps S., Foster P.S. Eosinophil trafficking in allergy and asthma. JAllergy Clin Immunol 2007, 119(6):1303-1310.
3. Larché M., Robinson D.S., Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. JAllergy Clin Immunol 2003, 111(3):450-463.
4. Hirasawa H., Chiba T., Ueki S., Kamada Y., Ito W., Takeda M., et al. The synthetic PPARγ agonist troglitazone inhibits eotaxin-enhanced eosinophil adhesion to ICAM-1-coated plates. Int Arch Allergy Immunol 2008, 146(Suppl.1):11-15.
5. Ueki S., Adachi T., Bourdeaux J., Oyamada H., Yamada Y., Hamada K., et al. Expression of PPARγ in eosinophils and its functional role in survival and chemotaxis. Immunol Lett 2003 Apr 3, 86(2):183-189.
6. Chihara J. Molecular mechanisms of eosinophil activation in allergic diseases. Clin Exp All Rev. 2005, 5:46-49.
7. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., McGarry M.P., O'Neill K.R., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004 Sep 17, 305(5691):1773-1776.
8. Ito W., Chiba T., Kanehiro A., Kato H., Yamaguchi K., Ueki S., et al. Hepatocyte growth factor attenuates eotaxin and PGD2-induced chemotaxis of human eosinophils. Allergy 2007 Apr, 62(4):415-422.
9. Wegmann M. Targeting eosinophil biology in asthma therapy. Am J Respir Cell Mol Biol. 2011 Oct, 45(4):667-674.
10. Kampen G.T., Stafford S., Adachi T., Jinquan T., Quan S., Grant J.A., et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 2000 Mar 15, 95(6):1911-1917.
11. Ito W., Takeda M., Fujita M., Kamada Y., Kato H., Chiba T., et al. Hepatocyte growth factor suppresses production of reactive oxygen species and release of eosinophil-derived neurotoxin from human eosinophils. Int Arch Allergy Immunol 2008, 147(4):331-337.
12. Toker A., Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997, 387:673-676.
13. Stephens L.R., Jackson T.R., Hawkins P.T. Agonist-stimulated synthesis of phosphatidylinositol (3,4,5)-trisphosphate: a new intracellular signalling system?. Biochim Biophys Acta 1993, 1179(1):27-75.
14. Takeda M., Ito W., Tanabe M., Ueki S., Kihara J., Kato H., et al. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation. Int Arch Allergy Immunol 2010, 152(Suppl.1):90-95.
15. Duan W., Aguinaldo Datiles A.M., Leung B.P., Vlahos C.J., Wong W.S. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 2005, 5(3):495-502.
16. Bi L., Okabe I., Bernard D.J., Wynshaw-Boris A., Nussbaum R.L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. JBiol Chem 1999, 274:10963-10968.
17. Bi L., Okabe I., Bernard D.J., Nussbaum R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002, 13:169-172.
18. Sasaki T., Irie-Sasaki J., Jones R.G., Oliveira-dos-Santos A.J., Stanford W.L., Bolon B., et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000 Feb 11, 287(5455):1040-1046.
19. Takeda M., Ito W., Tanabe M., Ueki S., Kato H., Kihara J., et al. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase γ-deficient mice. JAllergy Clin Immunol 2009 Apr, 123(4):805-812.
20. Lim D.H., Cho J.Y., Song D.J., Lee S.Y., Miller M., Broide D.H. PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol 2009 Feb, 296(2):L210-L219.
21. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008 Jan, 1784(1):159-185.
22. Camps M., Rückle T., Ji H., Ardissone V., Rintelen F., Shaw J., et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005 Sep, 11(9):936-943.
23. Barber D.F., Bartolomé A., Hernandez C., Flores J.M., Redondo C., et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005 Sep, 11(9):933-935.
24. Tanigai T., Ueki S., Kihara J., Kamada R., Yamauchi Y., Sokal A., et al. Docosahexaenoic acid exerts anti-inflammatory action on human eosinophils through peroxisome proliferator-activated receptor-independent mechanisms. Int Arch Allergy Immunol 2012, 158(4):375-386.
25. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. Aspecific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). JBiol Chem 1994 Feb 18, 269(7):5241-5248.
26. Ueki S., Kihara J., Kato H., Ito W., Takeda M., Kobayashi Y., et al. Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. Allergy 2009 May, 64(5):718-724.
27. Gleich G.J. Mechanisms of eosinophil-associated inflammation. JAllergy Clin Immunol 2000 Apr, 105(4):651-663.
28. Yamamura K., Adachi T., Masuda T., Kojima Y., Hara A., Toda T., et al. Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol 2009, 149(Suppl.1):45-50.
29. Adachi T., Hanaka S., Masuda T., Yoshihara H., Nagase H., Ohta K. Transduction of phosphatase and tensin homolog deleted on chromosome 10 into eosinophils attenuates survival, chemotaxis, and airway inflammation. JImmunol 2007 Dec 15, 179(12):8105-8111.
30. Mishra R.K., Scaife J.E., Harb Z., Gray B.C., Djukanovic R., Dent G. Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K). Allergy 2005 Sep, 60(9):1204-1207.
31. Ohashi P.S., Woodgett J.R. Modulating autoimmunity: pick your PI3 kinase. Nat Med 2005 Sep, 11(9):924-925.
32. Hasan A.M., Mourtada-Maarabouni M., Hameed M.S., Williams G.T., Dent G. Phosphoinositide 3-kinase γ mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol 2010 Sep, 10(9):1017-1021.
33. Ghigo A., Damilano F., Braccini L., Hirsch E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010 Mar, 32(3):185-196.
34. Adachi T., Stafford S., Kayaba H., Chihara J., Alam R. Myosin light chain kinase mediates eosinophil chemotaxis in a mitogen-activated protein kinase-dependent manner. JAllergy Clin Immunol 2003 Jan, 111(1):113-116.
35. Adachi T., Vita R., Sannohe S., Stafford S., Alam R., Kayaba H., et al. The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils. JImmunol 2001 Oct 15, 167(8):4609-4615.